Technical Analysis for LLY - Eli Lilly and Company

Grade Last Price % Change Price Change
grade A 117.09 2.10% 2.41
LLY closed up 2.1 percent on Tuesday, January 15, 2019, on approximately normal volume. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.

Earnings due: Jan 30

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Up Up
See historical LLY trend table...

Date Alert Name Type % Chg
Jan 15 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Jan 15 Pocket Pivot Bullish Swing Setup 0.00%
Jan 15 Stochastic Reached Overbought Strength 0.00%
Jan 15 Outside Day Range Expansion 0.00%
Jan 15 Overbought Stochastic Strength 0.00%
Jan 14 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 2.10%
Jan 14 Narrow Range Bar Range Contraction 2.10%
Jan 14 NR7 Range Contraction 2.10%
Jan 14 NR7-2 Range Contraction 2.10%
Jan 14 Overbought Stochastic Strength 2.10%

Older signals for LLY ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Eli Lilly and Company discovers, develops, manufactures, and sells pharmaceutical products worldwide. The company's neuroscience products treat major depressive disorders; schizophrenia, acute mixed or manic episodes associated with bipolar I disorder, and bipolar maintenance; attention-deficit hyperactivity disorder; depressive disorder, obsessive-compulsive disorder, bulimia nervosa, and panic disorder; bipolar depression and treatment-resistant depression; and brain imaging of beta-amyloid plaques. Its endocrinology products treat diabetes; osteoporosis in postmenopausal women and men at high risk of fracture; human growth hormone deficiency and pediatric growth conditions; and testosterone deficiency. The company's oncology products treat malignant pleural mesothelioma; pancreatic, metastatic breast, non-small cell lung, ovarian, bladder, colorectal, and head and neck cancers, as well as cardiovascular products, which are used treat erectile dysfunction, benign prostatic hyperplasia, high cholesterol, pulmonary arterial hypertension; reduce thrombotic cardiovascular events; and used as adjunct to percutaneous coronary intervention. In addition, it provides animal health products, such as cattle feed additives; antibiotics to treat respiratory and other diseases in cattle, swine, and poultry; leanness and performance enhancers for swine and cattle; protein supplements to improve milk productivity in dairy cows; anticoccidial agents; antibiotics to control enteric infections in calves and swine; products to treat canine separation anxiety; products that prevent flea infestations on dogs, kills fleas, prevent heartworm disease, and control intestinal parasite infections; and other pharmaceutical products to treat staphylococcal and bacterial infections. The company distributes its products through independent wholesale distributors; and directly to pharmacies. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Is LLY a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 119.84
52 Week Low 73.69
Average Volume 4,898,182
200-Day Moving Average 98.7311
50-Day Moving Average 112.9718
20-Day Moving Average 112.845
10-Day Moving Average 115.357
Average True Range 2.8863
ADX 10.94
+DI 26.2468
-DI 20.0193
Chandelier Exit (Long, 3 ATRs ) 109.5611
Chandelier Exit (Short, 3 ATRs ) 114.3289
Upper Bollinger Band 119.7458
Lower Bollinger Band 105.9442
Percent B (%b) 0.81
BandWidth 12.230582
MACD Line 1.0802
MACD Signal Line 0.716
MACD Histogram 0.3643
Fundamentals Value
Market Cap 123.53 Billion
Num Shares 1.05 Billion
EPS 2.31
Price-to-Earnings (P/E) Ratio 50.69
Price-to-Sales 4.03
Price-to-Book 6.30
PEG Ratio 1.77
Dividend 2.08
Dividend Yield 1.78%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 124.32
Resistance 3 (R3) 123.89 121.06 123.12
Resistance 2 (R2) 121.06 119.22 121.27 122.71
Resistance 1 (R1) 119.07 118.08 120.07 119.50 122.31
Pivot Point 116.24 116.24 116.73 116.45 116.24
Support 1 (S1) 114.25 114.40 115.25 114.68 111.87
Support 2 (S2) 111.42 113.26 111.63 111.47
Support 3 (S3) 109.43 111.42 111.07
Support 4 (S4) 109.86